<p>Cardiovascular aging is a key contributor to cardiovascular diseases (CVDs). As individuals age, the frequency and severity of cardiovascular events rise, establishing CVDs as a primary cause of death in older adults. Therefore, the development and exploration of drugs or bioactive molecules that can effectively prevent cardiovascular aging and related diseases are urgently needed. This study evaluated the effects of salidroside, a key component of <i>Rhodiola</i> <i>rosea</i> extract, on cardiomyocyte senescence. We established an in vitro cardiomyocyte senescence model using D-gal/H₂O₂ induction. A series of experimental techniques, including Western blot, indirect immunofluorescence, ELISA, and flow cytometry, were employed. The findings indicated that salidroside markedly reduced cardiomyocyte senescence in this model, as shown by Sa-β-gal staining and the evaluation of senescence-associated markers such as p16, p21, and p53. Additionally, salidroside reduced senescence-associated inflammation and oxidative stress levels. Additional mechanistic research demonstrated that salidroside promotes anti-aging by repairing DNA damage. In summary, this study systematically evaluated the potential biological activity of salidroside in combating cardiomyocyte aging and demonstrated its promising anti-aging effects. These findings suggest that salidroside could serve as a functional food ingredient with anti-aging properties, offering new strategies for preventing cardiovascular aging and related diseases.</p>